Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899537 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL899536 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17743844 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL903039 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17744011 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17743867 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17744012 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL15315277 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17147623 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 | |
| SCHEMBL17743870 | 1.00 | USP2 (0.54) | USP2HTTALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725720-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725720-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170015998-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015998-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-9458087-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458087-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
| WO-2012044638-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | USP2 3621/4885HTT 4217/4885ALDH1A1 4090/4885 |
| US-20170015998-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | USP2 3621/4885HTT 4217/4885ALDH1A1 4090/4885 |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | USP2 3621/4885HTT 4217/4885ALDH1A1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.